• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多基因二代测序分析中国高危乳腺癌患者同源重组修复基因的体细胞和生殖系畸变

Somatic and germline aberrations in homologous recombination repair genes among Chinese high-risk breast cancer patients by multi-gene next-generation sequencing.

作者信息

Xie Ling, Chen Jie, Zheng YanYing, Sun Yi, Zhang Xiang, Chu LeLe, Zhang YiFen

机构信息

Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China.

出版信息

Clin Transl Oncol. 2025 Feb;27(2):660-670. doi: 10.1007/s12094-024-03599-x. Epub 2024 Jul 24.

DOI:10.1007/s12094-024-03599-x
PMID:39043977
Abstract

INTRODUCTION

Recently, genes involved in homologous recombination repair (HRR) pathway have been extensively studied. However, the landscapes of HRR gene mutations remain poorly defined in Chinese high-risk breast cancer (BC) patients. Our study aims to identify the status of germline and somatic HRR gene mutations and their association with clinicopathological features in these patients.

MATERIALS AND METHODS

A total of 100 high-risk BC patients from our institution who underwent paired peripheral blood germline and BC tissues somatic 26 genes next-generation sequencing (NGS) from January 2018 to July 2023 were enrolled for retrospective analysis.

RESULTS

Out of 100 high-risk BC patients, 55 (55%) had at least one germline or somatic mutation in HRR genes. Among them, 22% carried germline pathogenic variants (19 BRCA1/2 and 3 non-BRCA genes), 9% harbored somatic pathogenic mutations (3 BRCA1/2 and 6 non-BRCA genes). Among high-risk factors, family history and early onset BC showed a correlation with HRR gene mutations (p < 0.05). BRCA1 germline and HRR gene somatic mutations showed a correlation with TNBC, but BRCA2 germline mutations were associated with Luminal B/HER2-negative BC (p < 0.05). Patients with HRR gene somatic pathogenic variant more likely had a lympho-vascular invasion and distant metastasis (p < 0.05).

CONCLUSION

The prevalence of HRR gene germline and somatic mutations were higher in Chinese BC patients with high risk factors. We strongly recommend that these high-risk BC patients receive comprehensive gene mutation testing, especially HRR genes, which are not only related to genetic consultation for BC patients and provide a theoretical basis for necessary prevention and individualized treatment.

摘要

引言

最近,参与同源重组修复(HRR)途径的基因受到了广泛研究。然而,在中国高危乳腺癌(BC)患者中,HRR基因突变的情况仍不清楚。我们的研究旨在确定这些患者中种系和体细胞HRR基因突变的状态及其与临床病理特征的关联。

材料与方法

对2018年1月至2023年7月期间在我院接受配对外周血种系和BC组织体细胞26基因下一代测序(NGS)的100例高危BC患者进行回顾性分析。

结果

在100例高危BC患者中,55例(55%)至少有一个HRR基因的种系或体细胞突变。其中,22%携带种系致病性变异(19个BRCA1/2和3个非BRCA基因),9%存在体细胞致病性突变(3个BRCA1/2和6个非BRCA基因)。在高危因素中,家族史和早发性BC与HRR基因突变相关(p<0.05)。BRCA1种系和HRR基因体细胞突变与三阴性乳腺癌(TNBC)相关,但BRCA2种系突变与Luminal B/HER2阴性BC相关(p<0.05)。HRR基因体细胞致病性变异的患者更易发生淋巴管浸润和远处转移(p<0.05)。

结论

中国有高危因素的BC患者中HRR基因种系和体细胞突变的发生率较高。我们强烈建议这些高危BC患者接受全面的基因突变检测,尤其是HRR基因,这不仅与BC患者的遗传咨询相关,还为必要的预防和个体化治疗提供理论依据。

相似文献

1
Somatic and germline aberrations in homologous recombination repair genes among Chinese high-risk breast cancer patients by multi-gene next-generation sequencing.通过多基因二代测序分析中国高危乳腺癌患者同源重组修复基因的体细胞和生殖系畸变
Clin Transl Oncol. 2025 Feb;27(2):660-670. doi: 10.1007/s12094-024-03599-x. Epub 2024 Jul 24.
2
[Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].[二代测序在BRCA1/2及同源重组修复通路多基因胚系突变检测中的应用及相关性分析]
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Mar 6;56(3):302-311. doi: 10.3760/cma.j.cn112150-20211208-01132.
3
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.同源重组修复基因存在或不存在体细胞或种系改变的转移性去势抵抗性前列腺癌患者的治疗模式及预后
Ann Oncol. 2024 May;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011. Epub 2024 Feb 27.
4
Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.使用下一代测序技术在中国胰腺导管腺癌患者中检测同源重组修复基因的种系突变。
Mol Genet Genomic Med. 2023 Jul;11(7):e2170. doi: 10.1002/mgg3.2170. Epub 2023 Mar 28.
5
Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.中国高危乳腺癌患者胚系非BRCA基因突变状态特征及其与高危因素的相关性和多基因检测建议
Front Genet. 2021 Nov 30;12:674094. doi: 10.3389/fgene.2021.674094. eCollection 2021.
6
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.BRCA1/2基因变异在中国未筛选乳腺癌患者中的患病率及预后作用
PLoS One. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789. eCollection 2016.
7
Germline Mutations in 32 Cancer Susceptibility Genes by Next-Generation Sequencing among Breast Cancer Patients.对乳腺癌患者中 32 个癌症易感基因的下一代测序进行种系突变分析。
Oncology. 2024;102(3):206-216. doi: 10.1159/000532095. Epub 2023 Jul 29.
8
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.考虑种系 BRCA1/2 突变状态的乳腺癌组织中同源重组修复(HRR)基因表达的改变。
Breast Cancer Res Treat. 2024 Dec;208(3):501-510. doi: 10.1007/s10549-024-07441-4. Epub 2024 Jul 30.
9
Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.台湾地区乳腺癌中同源重组修复基因肿瘤基因组改变的发生率。
Ann Surg Oncol. 2022 Jun;29(6):3578-3590. doi: 10.1245/s10434-022-11347-0. Epub 2022 Feb 28.
10
Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study.基于下一代测序的 700 例中国乳腺癌患者中 32 个癌症相关基因的种系变异:一项基于临床的观察性研究。
Int J Mol Sci. 2022 Sep 24;23(19):11266. doi: 10.3390/ijms231911266.

本文引用的文献

1
QTL analysis of sorghum grain traits based on high-density genetic map.基于高密度遗传图谱的高粱籽粒性状QTL分析
J Appl Genet. 2024 Sep 21. doi: 10.1007/s13353-024-00904-w.
2
Correction to: Novel FOXP2 variant associated with speech and language dysfunction in a Chinese family and literature review.对《一个中国家庭中与言语和语言功能障碍相关的新型FOXP2变异及文献综述》的勘误
J Appl Genet. 2024 May;65(2):417. doi: 10.1007/s13353-024-00851-6.
3
Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
同源重组修复缺陷状态与早期 HER2 低乳腺癌患者长期预后的关系:一项回顾性队列研究。
Oncologist. 2024 Jul 5;29(7):e864-e876. doi: 10.1093/oncolo/oyae021.
4
PARP Inhibitors in Breast Cancer: a Short Communication.聚腺苷二磷酸核糖聚合酶抑制剂在乳腺癌中的应用:一项简短通讯。
Curr Oncol Rep. 2024 Feb;26(2):103-113. doi: 10.1007/s11912-023-01488-0. Epub 2024 Jan 2.
5
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities.乳腺癌的综合基因组分析描绘了介导治疗易感性的种系-体细胞突变相互作用。
Cell Discov. 2023 Dec 19;9(1):125. doi: 10.1038/s41421-023-00614-3.
6
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?非 BRCA 相关性同源重组缺陷肿瘤患者的治疗性生物标志物和 PARP 抑制剂疗效:是否仍在雾里看花?
Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31.
7
Homologous Recombination Repair Deficiency: An Overview for Pathologists.同源重组修复缺陷:病理学家概述
Mod Pathol. 2023 Mar;36(3):100049. doi: 10.1016/j.modpat.2022.100049. Epub 2023 Jan 10.
8
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.聚(ADP - 核糖)聚合酶抑制剂的同源重组修复或同源重组缺陷检测:当前观点
Eur J Cancer. 2023 Jan;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub 2022 Nov 2.
9
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.肿瘤治疗中的 PARP 抑制剂的药代动力学和药效动力学。
Clin Pharmacokinet. 2022 Dec;61(12):1649-1675. doi: 10.1007/s40262-022-01167-6. Epub 2022 Oct 11.
10
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).癌症体细胞变异致病性分类标准(致癌性):临床基因组资源(ClinGen)、癌症基因组学联盟(CGC)和癌症变异解读联盟(VICC)的联合建议
Genet Med. 2022 Sep;24(9):1991. doi: 10.1016/j.gim.2022.07.001.